Literature DB >> 27388574

Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study.

Ru-Yu Huang1, Kun-Pin Hsieh1, Wan-Wen Huang1, Yi-Hsin Yang2.   

Abstract

BACKGROUND: Lithium inhibits glycogen synthase kinase-3, which is an enzyme involved in the pathogenesis of cancer. AIMS: To investigate the association between lithium and cancer risk in patients with bipolar disorder.
METHOD: A retrospective cohort study was designed using the National Health Insurance Research Database (NHIRD) in Taiwan. Patients using lithium comprised the index drug group and patients using anticonvulsants only comprised the control group. Time-dependent Cox regression was used to evaluate the hazard ratios (HRs) for risk of cancer.
RESULTS: Compared with anticonvulsant-only exposure, lithium exposure was associated with significantly lower cancer risk (HR = 0.735, 95% CI 0.554-0.974). The hazard ratios for the first, second and third tertiles of the cumulative defined daily dose were 0.762 (95% CI 0.516-1.125), 0.919 (95% CI 0.640-1.318) and 0.552 (95% CI 0.367-0.831), respectively.
CONCLUSIONS: Lithium is associated with reduced overall cancer risk in patients with bipolar disorder. A dose-response relationship for cancer risk reduction was observed. © The Royal College of Psychiatrists 2016.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27388574     DOI： 10.1192/bjp.bp.116.181362

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  24 in total

Review 1.  Using human experience to identify drug repurposing opportunities: theory and practice.

Authors:  D Cavalla
Journal:  Br J Clin Pharmacol       Date:  2019-02-03       Impact factor: 4.335

Review 2.  Neurodevelopmental Perspectives on Wnt Signaling in Psychiatry.

Authors:  Kimberly A Mulligan; Benjamin N R Cheyette
Journal:  Mol Neuropsychiatry       Date:  2017-01-13

3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

4.  Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome.

Authors:  Patrick K McCamphill; Laura J Stoppel; Rebecca K Senter; Michael C Lewis; Arnold J Heynen; David C Stoppel; Vinay Sridhar; Katie A Collins; Xi Shi; Jen Q Pan; Jon Madison; Jeffrey R Cottrell; Kimberly M Huber; Edward M Scolnick; Edward B Holson; Florence F Wagner; Mark F Bear
Journal:  Sci Transl Med       Date:  2020-05-20       Impact factor: 17.956

Review 5.  Can Stopping Nerves, Stop Cancer?

Authors:  Jami L Saloman; Kathryn M Albers; Andrew D Rhim; Brian M Davis
Journal:  Trends Neurosci       Date:  2016-11-08       Impact factor: 13.837

Review 6.  A regulatory loop connecting WNT signaling and telomere capping: possible therapeutic implications for dyskeratosis congenita.

Authors:  Rafael Jesus Fernandez; F Brad Johnson
Journal:  Ann N Y Acad Sci       Date:  2018-04       Impact factor: 5.691

7.  Uncovering Modern Clinical Applications of Fuzi and Fuzi-Based Formulas: A Nationwide Descriptive Study With Market Basket Analysis.

Authors:  Chi-Jung Tai; Mohamed El-Shazly; Yi-Hong Tsai; Dezső Csupor; Judit Hohmann; Yang-Chang Wu; Tzyy-Guey Tseng; Fang-Rong Chang; Hui-Chun Wang
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

8.  A Metallomic Approach to Assess Associations of Serum Metal Levels With Gallstones and Gallbladder Cancer.

Authors:  Mei-Hsuan Lee; Yu-Tang Gao; Yu-Han Huang; Emma E McGee; Tram Lam; Bingsheng Wang; Ming-Chang Shen; Asif Rashid; Ruth M Pfeiffer; Ann W Hsing; Jill Koshiol
Journal:  Hepatology       Date:  2019-11-01       Impact factor: 17.298

Review 9.  Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

Authors:  Huanjie Yang; Xin Chen; Kai Li; Hassan Cheaito; Qianqian Yang; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707

10.  Apc-mutant cells act as supercompetitors in intestinal tumour initiation.

Authors:  Sanne M van Neerven; Nina E de Groot; Lisanne E Nijman; Brendon P Scicluna; Milou S van Driel; Maria C Lecca; Daniël O Warmerdam; Vaishali Kakkar; Leandro F Moreno; Felipe A Vieira Braga; Delano R Sanches; Prashanthi Ramesh; Sanne Ten Hoorn; Arthur S Aelvoet; Marouska F van Boxel; Lianne Koens; Przemek M Krawczyk; Jan Koster; Evelien Dekker; Jan Paul Medema; Douglas J Winton; Maarten F Bijlsma; Edward Morrissey; Nicolas Léveillé; Louis Vermeulen
Journal:  Nature       Date:  2021-06-02       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.